Abstract
Lactobacillus strains are used in the functional food industry as promising probiotics with purported beneficial effects. We recently reported on the immunostimulatory effects of Lactobacillus sakei K040706 (K040706) in macrophages and in a cyclophosphamide-induced immunosuppression model. And this study assessed the anti-inflammatory effects and molecular mechanisms involving K040706 in a mouse model of colitis with dextran sodium sulfate (DSS). K040706 significantly attenuated the clinical signs and histological characteristics in DSS-induced colitic mice, which are well-correlated with the restoration of tight junction protein expression and the significant reduction of immune cell infiltration and expression of ICAM-1 and VCAM-1. Moreover, K040706 reduced the abnormal expression of pro-inflammatory mediators, such as iNOS, TNF-α, IL-1β, and IL-6, and the activation of NF-κB, STAT3 and TLR4. K040706 also improved the composition of intestinal microbiota. These results suggest K040706 has shown significant anti-inflammatory effects in a DSS-induced colitis model and has the potential to treat IBD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.